Details of the Drug

General Information of Drug (ID: DM60QMR)

Drug Name
Ethacrynic acid
Synonyms
Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
Indication
Disease Entry ICD 11 Status REF
Edema MG29 Approved [1]
High blood pressure BA00 Approved [2]
Therapeutic Class
Diuretics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 303.13
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.7 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.7126 micromolar/kg/day [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.26 L/kg [4]
Chemical Identifiers
Formula
C13H12Cl2O4
IUPAC Name
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
Canonical SMILES
CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
InChI
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
InChIKey
AVOLMBLBETYQHX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3278
ChEBI ID
CHEBI:4876
CAS Number
58-54-8
DrugBank ID
DB00903
TTD ID
D06TNL
VARIDT ID
DR00548
INTEDE ID
DR0653
ACDINA ID
D00251
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [8]
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [10]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Regulation of Drug Effects [11]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [12]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Gene/Protein Processing [12]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Protein Interaction/Cellular Processes [12]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Protein Interaction/Cellular Processes [12]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Protein Interaction/Cellular Processes [13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [13]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [10]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ethacrynic acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefuroxime DMSIMD8 Moderate Increased renal excretion of Ethacrynic acid caused by Cefuroxime. Acute bronchitis [CA42] [15]
Cefamandole DMNEXZF Moderate Increased renal excretion of Ethacrynic acid caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [15]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Dronedarone. Angina pectoris [BA40] [16]
Cefotetan DM07TX3 Moderate Increased renal excretion of Ethacrynic acid caused by Cefotetan. Bacterial infection [1A00-1C4Z] [15]
Kanamycin DM2DMPO Major Increased risk of ototoxicity by the combination of Ethacrynic acid and Kanamycin. Bacterial infection [1A00-1C4Z] [17]
Ceftizoxime DM3VOGS Moderate Increased renal excretion of Ethacrynic acid caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [15]
Cefoperazone DM53PV8 Moderate Increased renal excretion of Ethacrynic acid caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [15]
Cefprozil DM7DSYP Moderate Increased renal excretion of Ethacrynic acid caused by Cefprozil. Bacterial infection [1A00-1C4Z] [15]
Ceftriaxone DMCEW64 Moderate Increased renal excretion of Ethacrynic acid caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [15]
Streptomycin DME1LQN Major Increased risk of ototoxicity by the combination of Ethacrynic acid and Streptomycin. Bacterial infection [1A00-1C4Z] [17]
Cefepime DMHVWIK Moderate Increased renal excretion of Ethacrynic acid caused by Cefepime. Bacterial infection [1A00-1C4Z] [15]
Cefpodoxime DMJUNY5 Moderate Increased renal excretion of Ethacrynic acid caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [15]
Cefadroxil DMMC345 Moderate Increased renal excretion of Ethacrynic acid caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [15]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Ethacrynic acid and Rabeprazole. Bacterial infection [1A00-1C4Z] [18]
Netilmicin DMRD1QK Major Increased risk of nephrotoxicity by the combination of Ethacrynic acid and Netilmicin. Bacterial infection [1A00-1C4Z] [17]
Cefditoren DMSUVM1 Moderate Increased renal excretion of Ethacrynic acid caused by Cefditoren. Bacterial infection [1A00-1C4Z] [15]
Cefonicid DMTX2BH Moderate Increased renal excretion of Ethacrynic acid caused by Cefonicid. Bacterial infection [1A00-1C4Z] [15]
Cefradine DMUNSWV Moderate Increased renal excretion of Ethacrynic acid caused by Cefradine. Bacterial infection [1A00-1C4Z] [15]
Cefoxitin DMY8NC4 Moderate Increased renal excretion of Ethacrynic acid caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [15]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Cariprazine. Bipolar disorder [6A60] [19]
Etidronic acid DM1XHYJ Moderate Increased risk of hypocalcemia by the combination of Ethacrynic acid and Etidronic acid. Bone paget disease [FB85] [20]
Ceftibuten DMWV2AG Moderate Increased renal excretion of Ethacrynic acid caused by Ceftibuten. Bronchitis [CA20] [15]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Ethacrynic acid when combined with Ketoprofen. Chronic pain [MG30] [21]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Levomilnacipran. Chronic pain [MG30] [22]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Sertraline. Depression [6A70-6A7Z] [22]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Vilazodone. Depression [6A70-6A7Z] [22]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Selegiline. Depression [6A70-6A7Z] [23]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Vortioxetine. Depression [6A70-6A7Z] [22]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Isocarboxazid. Depression [6A70-6A7Z] [23]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Milnacipran. Depression [6A70-6A7Z] [22]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Escitalopram. Depression [6A70-6A7Z] [22]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Ethacrynic acid and OPC-34712. Depression [6A70-6A7Z] [19]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [24]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Ethacrynic acid and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [18]
Metipranolol DMJMVKI Moderate Increased risk of hyperglycemia by the combination of Ethacrynic acid and Metipranolol. Glaucoma [9C61] [25]
Levobetaxolol DMSREPX Moderate Increased risk of hyperglycemia by the combination of Ethacrynic acid and Levobetaxolol. Glaucoma [9C61] [25]
Levobunolol DMTNFCQ Moderate Increased risk of hypertriglyceridemia by the combination of Ethacrynic acid and Levobunolol. Glaucoma [9C61] [25]
Carvedilol DMHTEAO Moderate Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Carvedilol. Heart failure [BD10-BD1Z] [25]
Digitoxin DMWVIGP Moderate Increased risk of hypomagnesemia by the combination of Ethacrynic acid and Digitoxin. Heart failure [BD10-BD1Z] [26]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Procarbazine. Hodgkin lymphoma [2B30] [23]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Ethacrynic acid and Etelcalcetide. Hyper-parathyroidism [5A51] [27]
Acebutolol DM0TI4U Moderate Increased risk of hyperglycemia by the combination of Ethacrynic acid and Acebutolol. Hypertension [BA00-BA04] [25]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Captopril. Hypertension [BA00-BA04] [28]
Penbutolol DM4ES8F Moderate Increased risk of hyperglycemia by the combination of Ethacrynic acid and Penbutolol. Hypertension [BA00-BA04] [25]
Nebivolol DM7F1PA Moderate Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Nebivolol. Hypertension [BA00-BA04] [25]
Pindolol DMD2NV7 Moderate Increased risk of hypertriglyceridemia by the combination of Ethacrynic acid and Pindolol. Hypertension [BA00-BA04] [25]
Trichlormethiazide DMHAQCO Moderate Increased risk of fluid/electrolyte loss by the combination of Ethacrynic acid and Trichlormethiazide. Hypertension [BA00-BA04] [29]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of fluid/electrolyte loss by the combination of Ethacrynic acid and Hydrochlorothiazide. Hypertension [BA00-BA04] [29]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Ethacrynic acid when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [21]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Ethacrynic acid and ITI-007. Insomnia [7A00-7A0Z] [19]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Arsenic trioxide. Mature B-cell lymphoma [2A85] [30]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Ozanimod. Multiple sclerosis [8A40] [23]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Promethazine. Nausea/vomiting [MD90] [19]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Ethacrynic acid and Sibutramine. Obesity [5B80-5B81] [22]
Polythiazide DMCH80F Moderate Increased risk of fluid/electrolyte loss by the combination of Ethacrynic acid and Polythiazide. Oedema [MG29] [29]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Levomethadyl Acetate. Opioid use disorder [6C43] [31]
Carboplatin DMG281S Moderate Increased risk of ototoxicity by the combination of Ethacrynic acid and Carboplatin. Ovarian cancer [2C73] [32]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Ethacrynic acid when combined with Ibuprofen. Pain [MG30-MG3Z] [21]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Safinamide. Parkinsonism [8A00] [23]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Rasagiline. Parkinsonism [8A00] [23]
Bromfenac DMKB79O Moderate Antagonize the effect of Ethacrynic acid when combined with Bromfenac. Postoperative inflammation [1A00-CA43] [21]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Ethacrynic acid when combined with Oxaprozin. Rheumatoid arthritis [FA20] [21]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Quetiapine. Schizophrenia [6A20] [19]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Mesoridazine. Schizophrenia [6A20] [19]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Aripiprazole. Schizophrenia [6A20] [19]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Iloperidone. Schizophrenia [6A20] [33]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Paliperidone. Schizophrenia [6A20] [33]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Molindone. Schizophrenia [6A20] [19]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Thiothixene. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Amisulpride. Schizophrenia [6A20] [19]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Asenapine. Schizophrenia [6A20] [19]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Pimozide. Schizophrenia [6A20] [34]
Cephapirin DMV2JNY Moderate Increased renal excretion of Ethacrynic acid caused by Cephapirin. Sepsis [1G40-1G41] [15]
Plazomicin DMKMBES Major Increased risk of ototoxicity by the combination of Ethacrynic acid and Plazomicin. Urinary tract infection [GC08] [17]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Ethacrynic acid and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [19]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Ethacrynic acid and Amiodarone. Ventricular tachyarrhythmia [BC71] [35]
⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ethacrynic acid 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Ethacrynic acid FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7179).
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
7 Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160-6.
8 Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
9 Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
10 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
11 Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005 Jul;35(7):737-53.
12 Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18.
13 Genotoxic effect of ethacrynic acid and impact of antioxidants. Toxicol Appl Pharmacol. 2015 Jul 1;286(1):17-26. doi: 10.1016/j.taap.2015.03.016. Epub 2015 Mar 25.
14 Curcumin-induced GADD153 upregulation: modulation by glutathione. J Cell Biochem. 2007 May 15;101(2):307-20. doi: 10.1002/jcb.21179.
15 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
16 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
17 Bates DE, Beaumont SJ, Baylis BW "Ototoxicity induced by gentamicin and furosemide." Ann Pharmacother 36 (2002): 446-51. [PMID: 11895059]
18 Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
19 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
21 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
22 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
23 Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
24 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
25 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
26 Semple P, Tilstone WJ, Lawson DH "Furosemide and urinary digoxin clearance." N Engl J Med 293 (1975): 612-3. [PMID: 902451]
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
29 Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
30 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
31 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
32 Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
33 Cerner Multum, Inc. "Australian Product Information.".
34 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
35 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]